Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Q3 2025 value amounting to $549000.0.

  • Lineage Cell Therapeutics' Receivables - Other changed N/A to $549000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $549000.0, marking a year-over-year change of. This contributed to the annual value of $581000.0 for FY2022, which is 859.81% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Receivables - Other of $549000.0 as of Q3 2025.
  • Lineage Cell Therapeutics' 5-year Receivables - Other high stood at $581000.0 for Q4 2022, and its period low was $200000.0 during Q2 2022.
  • Over the past 3 years, Lineage Cell Therapeutics' median Receivables - Other value was $545000.0 (recorded in 2022), while the average stood at $482000.0.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Receivables - Other was 859.81% (2022), while the steepest drop was 859.81% (2022).
  • Lineage Cell Therapeutics' Receivables - Other (Quarter) stood at $535000.0 in 2021, then grew by 8.6% to $581000.0 in 2022, then dropped by 5.51% to $549000.0 in 2025.
  • Its last three reported values are $549000.0 in Q3 2025, $581000.0 for Q4 2022, and $545000.0 during Q3 2022.